|
Aug 13
|
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
|
|
May 10
|
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines
|
|
May 10
|
Q1 2024 Lineage Cell Therapeutics Inc Earnings Call
|
|
May 9
|
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 6
|
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
|
|
May 2
|
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
|
|
Apr 30
|
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
|
|
Apr 29
|
Lineage Announces Changes to Board of Directors
|
|
Apr 19
|
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By
|
|
Apr 1
|
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
|
|
Mar 18
|
15 Best Anti-Aging Foods for Youthful Skin
|
|
Mar 18
|
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
|
|
Mar 14
|
Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
|
|
Mar 13
|
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
|
|
Mar 11
|
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
|
|
Mar 8
|
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript
|
|
Mar 8
|
Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results
|
|
Mar 7
|
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Jan 16
|
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
|